Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
BMC Cancer ; 24(1): 174, 2024 Feb 05.
Article in English | MEDLINE | ID: mdl-38317104

ABSTRACT

BACKGROUND: High levels of physical activity are associated with reduced risk of the blood cancer multiple myeloma (MM). MM is preceded by the asymptomatic stages of monoclonal gammopathy of undetermined significance (MGUS) and smouldering multiple myeloma (SMM) which are clinically managed by watchful waiting. A case study (N = 1) of a former elite athlete aged 44 years previously indicated that a multi-modal exercise programme reversed SMM disease activity. To build from this prior case study, the present pilot study firstly examined if short-term exercise training was feasible and safe for a group of MGUS and SMM patients, and secondly investigated the effects on MGUS/SMM disease activity. METHODS: In this single-arm pilot study, N = 20 participants diagnosed with MGUS or SMM were allocated to receive a 16-week progressive exercise programme. Primary outcome measures were feasibility and safety. Secondary outcomes were pre- to post-exercise training changes to blood biomarkers of MGUS and SMM disease activity- monoclonal (M)-protein and free light chains (FLC)- plus cardiorespiratory and functional fitness, body composition, quality of life, blood immunophenotype, and blood biomarkers of inflammation. RESULTS: Fifteen (3 MGUS and 12 SMM) participants completed the exercise programme. Adherence was 91 ± 11%. Compliance was 75 ± 25% overall, with a notable decline in compliance at intensities > 70% V̇O2PEAK. There were no serious adverse events. There were no changes to M-protein (0.0 ± 1.0 g/L, P =.903), involved FLC (+ 1.8 ± 16.8 mg/L, P =.839), or FLC difference (+ 0.2 ± 15.6 mg/L, P =.946) from pre- to post-exercise training. There were pre- to post-exercise training improvements to diastolic blood pressure (- 3 ± 5 mmHg, P =.033), sit-to-stand test performance (+ 5 ± 5 repetitions, P =.002), and energy/fatigue scores (+ 10 ± 15%, P =.026). Other secondary outcomes were unchanged. CONCLUSIONS: A 16-week progressive exercise programme was feasible and safe, but did not reverse MGUS/SMM disease activity, contrasting a prior case study showing that five years of exercise training reversed SMM in a 44-year-old former athlete. Longer exercise interventions should be explored in a group of MGUS/SMM patients, with measurements of disease biomarkers, along with rates of disease progression (i.e., MGUS/SMM to MM). REGISTRATION: https://www.isrctn.com/ISRCTN65527208 (14/05/2018).


Subject(s)
Monoclonal Gammopathy of Undetermined Significance , Multiple Myeloma , Paraproteinemias , Smoldering Multiple Myeloma , Humans , Adult , Monoclonal Gammopathy of Undetermined Significance/therapy , Monoclonal Gammopathy of Undetermined Significance/diagnosis , Multiple Myeloma/diagnosis , Pilot Projects , Quality of Life , Disease Progression , Biomarkers , Exercise
3.
Cochrane Database Syst Rev ; (3): CD004487, 2007 Jul 18.
Article in English | MEDLINE | ID: mdl-17636762

ABSTRACT

BACKGROUND: Paracetamol has been commonly used for the relief of postoperative pain following oral surgery. In this review we investigated the optimal dose of paracetamol and the optimal time for drug administration to provide pain relief, taking into account the side effects of different doses of the drug. This will inform dentists and their patients of the best strategy for pain relief after the surgical removal of wisdom teeth. OBJECTIVES: To assess the beneficial and harmful effects of paracetamol for pain relief after surgical removal of lower wisdom teeth, compared to placebo, at different doses and administered postoperatively. SEARCH STRATEGY: We searched the Cochrane Oral Health Group's Trials Register; the Cochrane Pain, Palliative and Supportive Care Group's Trials Register; CENTRAL; MEDLINE; EMBASE and the Current Controlled Trials Register. Handsearching included several dental journals. We checked the bibliographies of relevant clinical trials and review articles for studies outside the handsearched journals. We wrote to authors of the identified randomised controlled trials (RCTs), to manufacturers of analgesic pharmaceuticals, we searched personal references in an attempt to identify unpublished or ongoing RCTs. No language restriction was applied. The last electronic search was conducted on 24th August 2006. SELECTION CRITERIA: Randomised, parallel group, placebo controlled, double blind clinical trials of paracetamol for acute pain, following third molar surgery. DATA COLLECTION AND ANALYSIS: All trials identified were scanned independently and in duplicate by two review authors, any disagreements were resolved by discussion, or if necessary a third review author was consulted. The proportion of patients with at least 50% pain relief was calculated for both paracetamol and placebo. The number of patients experiencing adverse events, and/or the total number of adverse events reported were analysed. MAIN RESULTS: Twenty-one trials met the inclusion criteria. A total of 2048 patients were initially enrolled in the trials (1148 received paracetamol, and 892 the placebo) and of these 1968 (96%) were included in the meta-analysis (1133 received paracetamol, and 835 the placebo). Paracetamol provided a statistically significant benefit when compared with placebo for pain relief and pain intensity at both 4 and 6 hours. Most studies were found to have moderate risk of bias, with poorly reported allocation concealment being the main problem. Risk ratio values for pain relief at 4 hours 2.85 (95% confidence interval (CI) 1.89 to 4.29), and at 6 hours 3.32 (95% CI 1.88 to 5.87). A statistically significant benefit was also found between up to 1000 mg and 1000 mg doses, the higher the dose giving greater benefit for each measure at both time points. There was no statistically significant difference between the number of patients who reported adverse events, overall this being 19% in the paracetamol group and 16% in the placebo group. AUTHORS' CONCLUSIONS: Paracetamol is a safe, effective drug for the treatment of postoperative pain following the surgical removal of lower wisdom teeth.


Subject(s)
Acetaminophen/therapeutic use , Analgesics, Non-Narcotic/therapeutic use , Molar, Third/surgery , Pain, Postoperative/drug therapy , Tooth Extraction/adverse effects , Acetaminophen/adverse effects , Analgesics, Non-Narcotic/adverse effects , Humans , Outcome Assessment, Health Care , Pain Measurement , Randomized Controlled Trials as Topic
4.
Br Dent J ; 217(5): 231-4, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25213519

ABSTRACT

The aims of the study were to develop a method of quantifying denture cleanliness and evaluate the quality of clinical record keeping; record baseline denture cleanliness for 30 patients; introduce denture hygiene instruction (DHI); and then re-assess the patients for improvement and enhanced record keeping. A retrospective analysis of denture hygiene instruction record keeping was undertaken (n = 30). A bespoke denture cleanliness index (DCI) was developed for assessing denture cleanliness (best score 0, worst score 4). Baseline DCI scores were taken and individual DHI was delivered. Patients were reviewed and scored after 1 month, together with a further analysis of record keeping. At baseline, 16% (n = 5) of patients had DCI scores of ≤2, improving to 90% (n = 27) after 1 month, demonstrating short term improvement in denture cleanliness. Only 20% (n = 6) of patients had evidence of a record of DHI within their notes at baseline, improving to 100% at recall. The bespoke denture cleanliness index (DCI) worked well as a simple objective clinical measurement and patient education tool. Provision of tailored DHI resulted in the general improvement of denture cleanliness after 1 month. The authors recommend that where denture hygiene has been issued, this should be recorded in the records as 'DHI' within the clinical notes, in a manner analogous to the recording of oral hygiene.


Subject(s)
Dentures , Hygiene , Medical Audit , Practice Management, Dental/organization & administration , England , Humans , Retrospective Studies
6.
Int J Paediatr Dent ; 15(2): 136-9, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15790373

ABSTRACT

Primary herpetic gingivostomatitis is a relatively common and well-recognized condition that the dental practitioner may encounter in clinical practice. A primary herpetic infection in a child with atopic dermatitis such as eczema, however, predisposes them to eczema herpeticum. This can be a severe and potentially life-threatening condition. This paper describes one such case, discusses the aetiology, presentation and management of this condition, and highlights the importance of early recognition by the clinician.


Subject(s)
Kaposi Varicelliform Eruption/diagnosis , Stomatitis, Herpetic/diagnosis , Diagnosis, Differential , Facial Dermatoses/virology , Humans , Infant , Male
SELECTION OF CITATIONS
SEARCH DETAIL